Treatment of non-alcoholic steatohepatitis

Paul Angulo, Keith Lindor

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but is not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, α-tocopherol, metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NASH. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow-up. A better understanding of the pathogenesis and natural history of NASH will help to identify the subset of patients at risk of progressing to advanced liver disease and, hence, those patients who should derive the most benefit from medical therapy.

Original languageEnglish (US)
Pages (from-to)797-810
Number of pages14
JournalBailliere's Best Practice and Research in Clinical Gastroenterology
Volume16
Issue number5
DOIs
StatePublished - Oct 2002
Externally publishedYes

Fingerprint

Fatty Liver
Weight Loss
Obesity
Gemfibrozil
Ursodeoxycholic Acid
Betaine
Tocopherols
Metformin
Acetylcysteine
Therapeutics
Hyperlipidemias
Natural History
Liver Diseases
Diabetes Mellitus
Lipids
Glucose
Liver

Keywords

  • Diabetes mellitus
  • Hyperlipidaemia
  • Insulin resistance
  • NASH
  • Non-alcoholic fatty liver
  • Obesity
  • Treatment
  • Tumour necrosis factor
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of non-alcoholic steatohepatitis. / Angulo, Paul; Lindor, Keith.

In: Bailliere's Best Practice and Research in Clinical Gastroenterology, Vol. 16, No. 5, 10.2002, p. 797-810.

Research output: Contribution to journalArticle

@article{8ff8f924c51743f9ace2faffc358acac,
title = "Treatment of non-alcoholic steatohepatitis",
abstract = "Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but is not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, α-tocopherol, metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NASH. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow-up. A better understanding of the pathogenesis and natural history of NASH will help to identify the subset of patients at risk of progressing to advanced liver disease and, hence, those patients who should derive the most benefit from medical therapy.",
keywords = "Diabetes mellitus, Hyperlipidaemia, Insulin resistance, NASH, Non-alcoholic fatty liver, Obesity, Treatment, Tumour necrosis factor, Ursodeoxycholic acid",
author = "Paul Angulo and Keith Lindor",
year = "2002",
month = "10",
doi = "10.1053/bega.2002.0327",
language = "English (US)",
volume = "16",
pages = "797--810",
journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",
issn = "1521-6918",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of non-alcoholic steatohepatitis

AU - Angulo, Paul

AU - Lindor, Keith

PY - 2002/10

Y1 - 2002/10

N2 - Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but is not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, α-tocopherol, metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NASH. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow-up. A better understanding of the pathogenesis and natural history of NASH will help to identify the subset of patients at risk of progressing to advanced liver disease and, hence, those patients who should derive the most benefit from medical therapy.

AB - Treatment of patients with non-alcoholic steatohepatitis (NASH) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidaemia. NASH associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but is not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, α-tocopherol, metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NASH. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow-up. A better understanding of the pathogenesis and natural history of NASH will help to identify the subset of patients at risk of progressing to advanced liver disease and, hence, those patients who should derive the most benefit from medical therapy.

KW - Diabetes mellitus

KW - Hyperlipidaemia

KW - Insulin resistance

KW - NASH

KW - Non-alcoholic fatty liver

KW - Obesity

KW - Treatment

KW - Tumour necrosis factor

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0036781495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036781495&partnerID=8YFLogxK

U2 - 10.1053/bega.2002.0327

DO - 10.1053/bega.2002.0327

M3 - Article

VL - 16

SP - 797

EP - 810

JO - Bailliere's Best Practice and Research in Clinical Gastroenterology

JF - Bailliere's Best Practice and Research in Clinical Gastroenterology

SN - 1521-6918

IS - 5

ER -